Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes

Journal of Diabetes and its Complications

Volumn 29, Issue 1, 2015, Pages 5-12

  Xu, Pengfei ^a   Ye, Xianlong ^a   Zhang, Yingjie ^a   Yuan, Qingyan ^a   Liu, Mingyao ^a   Wu, Qiang ^a   Ren, Guiping ^a   Li, Deshan ^a  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

Author keywords

FGF21; Gluconeogenesis; Glycolysis; Insulin glargine; Long acting hypoglycemic effects; PEGylated; Type 1 diabetic mice

Indexed keywords

GLUCOKINASE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; INSULIN GLARGINE; MESSENGER RNA; PEGYLATED FIBROBLAST GROWTH FACTOR 21; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); RECOMBINANT FIBROBLAST GROWTH FACTOR; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 21; GLUCOSE BLOOD LEVEL; INSULIN; INSULIN, POLYETHYLENE GLYCOL(B1)-; MACROGOL DERIVATIVE; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL MODEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCOLYSIS; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ANALOGS AND DERIVATIVES; ANALYSIS; ANIMAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; INSTITUTE FOR CANCER RESEARCH MOUSE; PATHOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES; RANDOMIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR; TREATMENT OUTCOME;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FIBROBLAST GROWTH FACTORS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN GLARGINE; MALE; MICE; MICE, INBRED ICR; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; RANDOM ALLOCATION; RNA, MESSENGER; STREPTOZOCIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84920528486     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2014.10.001     Document Type: Article

References (32)

1. L. Agius Targeting hepatic glucokinase in type 2 diabetes weighing the benefits and risks Diabetes 58 1 2009 18 20
2. Y. Chen, J.J. Wang, J. Li, K.I. Hosoya, R. Ratan, and T. Townes Activating transcription factor 4 mediates hyperglycaemia-induced endothelial inflammationand retinal vascular leakage through activation of STAT3 in a mouse model of type 1 diabetes Diabetologia 55 2012 2533 2545
3. H.M. Colhoun, and SDRN Epidemiology Group Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research Network Epidemiology Group Diabetologia 52 2009 1755 1765
4. S.W. Cushman, and L.J. Wardzala Potential mechanism of insulin action on glucose transport in the isolated rat adipose cell. Apparent translocation of intracellular transport systems to the plasma membrane Journal of Biological Chemistry 255 1980 4758 4762
5. Z.K.A. Galzie, and J.A. Smith Fibroblast growth factors and their receptors Biochemistry and Cell Biology 75 1997 669 685
6. W. Glaesner, R. Rathnachalam, and R. Millican Glycol linked Fgf-21 compounds 2005 (US 20070265200 A1)
7. B.A. Haber, S. Chin, E. Chuang, W. Buikhuisen, A. Naji, and R. Taub High levels of glucose 6-phosphatase gene and protein expression reflect an adaptive response in proliferating liver and diabetes Journal of Clinical Investigation 95 2 1995 832 841
8. B.L. Hogan Morphogenesis Cell 96 1999 225 233
9. Z. Huang, H. Wang, and M. Lu A better anti-diabetic recombinant human fibroblast growth factor 21(rhFGF21) modified with polyethylene glycol PLoS ONE 6 6 2011 e20669
10. A. Kharitonenkov, T.L. Shiyanova, A. Koester, A.M. Ford, and R. Micanovic FGF-21 as a novel metabolic regulator Journal of Clinical Investigation 115 2005 1627 1635
11. A. Kharitonenkov, and V.J. Wroblewski The metabolic state of diabetic monkeys is regulated by FGF-21 Endocrinology 148 2 2007 774 781
12. A. Kharitonenkov, V.J. Wroblewski, A. Koester, Y.F. Chen, and C.K. Clutinger The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21 Endocrinology 148 2007 774 781
13. J. Li, J.J. Wang, Q. Yu, M. Wang, and S.X. Zhang Endoplasmic reticulum stress is implicated in retinal inflammation and diabetic retinopathy FEBS Letters 583 2009 1521 1527
14. L. Lu, C.P. Seidel, T. Iwase, R.K. Stevens, Y.Y. Gong, and X. Wang Suppression of GLUT1; A new strategy to prevent diabetic complications Journal of Cellular Physiology 228 2 2013 251 257
15. K. McKeage, and K.L. Goa Insulin glargine Drugs 61 11 2001 1599 1624
16. W.L. McKeehan, F. Wang, and M. Kan The heparan sulfate-fibroblast growth factor family: Diversity of structure and function Progress in Nucleic Acid Research and Molecular Biology 59 1998 135 176
17. D.M. Ornitz, and N. Itoh Fibroblast growth factors Genome Biology 2 3 2001
18. C.J. Powers MSaWA: Fibroblast growth factors, their receptors and signaling Endocrine-Related Cancer 7 2000 165 197
19. K. Prasad Suppression of phosphoenolpyruvate carboxykinase gene expression by secoisolariciresinol diglucoside (SDG), a new antidiabetic agent Biochimica et Biophysica Acta 1772 10 2007 1175 1181
20. M. Presta, P. Dell'Era, S. Mitola, E. Moroni, R. Ronca, and M. Rusnati Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis Cytokine and Growth Factor Reviews 16 2005 159 178
21. Sanofi-Aventis LANTUS (insulin glargine [rDNA origin] injection) Available from http://products.sanofi-aventis.us/lantus/lantus.pdf 2007 (accessed 15 May 2009)
22. T. Sato, A. Toyoshima, T. Hiraki, Y. Ohta, and K. Katayama Effects of metformin on plasma concentrations of glucose and mannose, G6Pase and PEPCK activity, and mRNA expression in the liver and kidney of chickens British Poultry Science 52 2 2011 273 277
23. Shanaka Stanislaus, Jing Xu, and Murielle Marie Ellison Method of treating or ameliorating type 1 diabetes using fgf21 2013 (WO 2013033452 A2)
24. K. Suzuki, and T. Kono Evidence that insulin causes translocation of glucose transport activity to the plasma membrane from an intracellular storage site Proceedings of the National Academy of Sciences of the United States of America 77 5 1980 2542 2545
25. Y. Terauchi, H. Sakura, K. Yasuda, and K. Iwamoto Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose Journal of Biological Chemistry 270 51 1995 30253 30256
26. F. Tremblay, C. Lavigne, H. Jacques, and A. Marette Defective insulin-induced GLUT4 translocation in skeletal muscle of high fat-fed rats is associated with alterations in both Akt/protein kinase B and atypical protein kinase C (z/l) activities Diabetes 50 2001 81901 81910
27. F. Wang, J.M. Carabino, and C.M. Vergara Insulin glargine: A systematic review of a long-acting insulin analogue Clinical Therapeutics 25 6 2003 1541 1577
28. H. Wang, Y. Xiao, L. Fu, H. Zhao, and Y. Zhang High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli BMC Biotechnology 10 2010 14
29. D. Warriner, M. Debono, R.A. Gandhi, E. Chong, and F. Creagh Acute hepatic injury following treatment of a long-acting insulin analogue overdose necessitating urgent insulin depot excision Diabetic Medicine 29 2 2012 232 235
30. W. Wente, A.M. Efanov, M. Brenner, and A. Kharitonenkov Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways Diabetes 55 9 2006 2470 2478
31. J. Xu, D.J. Lloyd, C. Hale, S. Stanislaus, and M. Chen Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice Diabetes 58 2009 250 259
32. N. Younis, H. Soran, and D. Bowen-Jones Insulin glargine: A new basal insulin analogue QJM 95 11 2002 757 761